Please select the option that best describes you:
Do you recommend MSI testing to any tumor that is not already eligible for immunotherapy?
Given recent FDA accelerated approval of pembrolizumab for MSI-H tumors regardless of site of origin, does it make sense to apply MSI testing, in particular about cancer of unknown primary, breast, and pancreatic?
Answer from: Medical Oncologist at Academic Institution
The accelerated approval of pembrolizumab in MSI-H tumors was based on data from 149 pateints with MSI-H or dMMR cancers from five different single arm studies. Ninety of those patients were colorectal, the remaining 59 were a mix of 14 different types. The ORR for the entire group was almost 40% wi...
Sign in or Register to read more